N/A
N=21
The Smartlipo Triplex 1440nm Wavelength Laser and the Sidelaze 800 Hand Piece for the Treatment of Facial Acne Scars
Acne Scars
Bottom Line
View on ClinicalTrials.gov: NCT02103816 ↗Enrolled (actual)
21
Serious AEs
0.0%
Results posted
Dec 2020
Primary outcome: Primary: Percentage of Participants With Facial Acne Improvement Using the Global Aesthetic Improvement Scale — 28.6; 57.1; 14.3 percentage of participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- SmartLipo Triplex laser system along with the SideLaze800 hand piece (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Cynosure, Inc.
- Primary completion
- Feb 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Facial Acne Improvement Using the Global Aesthetic Improvement Scale |
28.6; 57.1; 14.3 | — |
| SECONDARY Investigator Satisfaction Questionnaire |
6; 5; 3 | — |
| SECONDARY Subject Satisfaction Questionnaire |
6; 6; 2; 1 | — |
Summary
The purpose of this study to evaluate the SmartLipo Triplex laser system along with the SideLaze800 hand piece in the treatment of Acne Scars.
Eligibility Criteria
Inclusion Criteria
- A healthy male or female between 18 and 65 years old
- Has unwanted facial acne scars and wishes to undergo laser treatments.
- Is willing to consent to participate in the study.
- Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending follow up visits.
Exclusion Criteria
- The subject is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.
- The subject is hypersensitive to light exposure OR takes photo sensitized medication.
- The subject has active or localized systemic infections.
- The subject has a coagulation disorder or is currently using anti-coagulation medication (including but not limited to the heavy use of aspirin) {greater than 81 mg per day}).
- The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within the planned treatment area 3 months prior to entering this study.
- The subject has used Accutane within 6 months prior to enrollment.
- The subject has the need to be exposed to artificial tanning devices or excessive sunlight during the trial.
- The subject has had prior treatment with parenteral gold therapy (gold sodium thiomalate).
- The subject has a history of keloids.
- The subject has evidence of compromised wound healing.
- The subject has a history of squamous cell carcinoma or melanoma.
- The subject has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications.
- The subject has an allergy to lidocaine and epinephrine.
- The subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
Data sourced from ClinicalTrials.gov (NCT02103816). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.